Form 4: Exact Sciences CEO Kevin Conroy Reports Stock Transactions

CEO Kevin Conroy reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Summary

• On February 29, 2024, Kevin Conroy, CEO of Exact Sciences Corp, acquired 18,143 shares of common stock upon the vesting of restricted stock units.
• On March 1, 2024, Conroy sold 8,271 shares of common stock at a price of $59.32 per share.
• The sale was executed pursuant to a Sell-to-Cover Rule 10b5-1 Plan to cover withholding taxes related to the vesting of the restricted stock units.
• Following these transactions, Conroy directly owns 1,299,496 shares of common stock.
• Conroy also indirectly owns 27,924 shares held in a 401(k) plan and 65,189 shares held in Grantor Retained Annuity Trusts.
• In addition to the directly and indirectly held shares, Conroy holds 683,018 vested and unvested options and restricted stock units.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are routine and related to compensation and tax obligations. No strong positive or negative signals are apparent.

Positives

• The vesting of restricted stock units indicates confidence in the company's future performance.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors.

Risks

• Executive stock sales can sometimes create short-term price volatility.

Industry Context

Insider transactions are routinely monitored and reported, providing transparency into executive sentiment and potential stock movements. These transactions are common and often related to compensation plans.

Comparison to Industry Standards

• Sell-to-cover transactions are a standard practice among executives receiving stock-based compensation.
• The volume of shares sold is relatively small compared to Conroy's total holdings, suggesting it's primarily for tax obligations.
• Comparing Conroy's holdings and transactions to those of CEOs at similar diagnostic companies (e.g., Guardant Health, Foundation Medicine) can provide a benchmark for executive ownership.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on stakeholders, as they are routine and related to executive compensation.

Key Dates